Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness.
- Author:
Seon Rang WOO
1
;
Young Taek OH
;
Jae Yeol AN
;
Bong Gu KANG
;
Do Hyun NAM
;
Kyeung Min JOO
Author Information
- Publication Type:In Vitro ; Original Article
- Keywords: Glioblastoma multiforme; Cancer stem cell; Therapeutic marker; GD2; CD90
- MeSH: Adult; Brain Neoplasms; Drug Therapy; Glioblastoma*; Humans; Neoplastic Stem Cells; Neural Stem Cells; Prognosis; World Health Organization
- From:Anatomy & Cell Biology 2015;48(1):44-53
- CountryRepublic of Korea
- Language:English
- Abstract: Glioblastoma multiforme (GBM) is the most malignant World Health Organization grade IV brain tumor. GBM patients have a poor prognosis because of its resistance to standard therapies, such as chemotherapy and radiation. Since stem-like cells have been associated with the treatment resistance of GBM, novel therapies targeting the cancer stem cell (CSC) population is critically required. However, GBM CSCs share molecular and functional characteristics with normal neural stem cells (NSCs). To elucidate differential therapeutic targets of GBM CSCs, we compared surface markers of GBM CSCs with adult human NSCs and found that GD2 and CD90 were specifically overexpressed in GBM CSCs. We further tested whether the GBM CSC specific markers are associated with the cancer stemness using primarily cultured patient-derived GBM cells. However, results consistently indicated that GBM cells with or without GD2 and CD90 had similar in vitro sphere formation capacity, a functional characteristics of CSCs. Therefore, GD2 and CD90, GBM specific surface markers, might not be used as specific therapeutic targets for GBM CSCs, although they could have other clinical utilities.
